APELLIS PHARMACEUTICALS INC (APLS) Stock News
NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD
APLS Latest News, Press Relases and Analysis
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
The company had some encouraging regulatory news to report. It concerned a dermatitis drug the biotech is currently developing. Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on Monday.
Apellis price target lowered to $20 from $28 at Scotiabank
Scotiabank analyst Greg Harrison lowered the firm’s price target on Apellis (APLS) to $20 from $28 and keeps a Sector Perform rating on the shares. The company had a weak Q1, with Syfovre revenues in geographic atrophy missing expectations due to underfunding of retinal therapeutics co-pay assistance programs and inventory draw down, the analyst tells investors. The firm is lowering its price target on the stock to reflect its updated expectations for Syfovre sales. Published first on TheFly – t
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Kenvue expects flat profit as $150 million tariff hit looms
(Reuters) -Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a $150 million impact from President Donald Trump's trade tariffs implemented on U.S. imports thus far. Kenvue will work with retail partners on targeted pricing actions in a way that will "preserve the long-term health of our brands" and "minimize the impact for our consumers", CEO Thibaut Mongon said in a call with analysts. Shares of New Jersey-based Kenvue rose 6% in morning trading.
How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock
Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S. and internationally. The 52-week range of Gilead Sciences stock price was $62.07 to ...
Core & Main, Inc. (NYSE:CNM): Better Days in the Pipeline
We came across a bullish thesis on Core & Main, Inc. (NYSE:CNM) on ValueInvestorsClub by yellow. In this article, we will summarize the bulls’ thesis on CNM. The company’s shares were trading at $48.00 when this thesis was published, vs. the closing price of $52.53 on Apr 25. CNM distributes water, wastewater, storm drainage, and […]
Forward Air touts Q1 achievements, investors await next steps
Forward Air’s first-quarter update provides investors with little insight into an ongoing strategic review of the company. The post Forward Air touts Q1 achievements, investors await next steps appeared first on FreightWaves.
Bank of England set to cut rates amid worries about Trump tariff fallout
LONDON (Reuters) -The Bank of England is poised to extend its slow run of interest rate cuts on Thursday with investors watching for any signs that it could soon pick up the pace as U.S. President Donald Trump's tariffs weigh on the world economy. Governor Andrew Bailey and his BoE colleagues have long stressed the need for a gradual and careful approach to lowering borrowing costs, something most analysts say is likely to continue given the scale of uncertainty about the outlook. The BoE has cut rates just three times so far since last August, moving more slowly than the U.S. Federal Reserve and the European Central Bank due to its concerns about inflationary heat in the jobs market.
DexCom, Inc. (DXCM): A Bull Case Theory
We came across a bullish thesis on DexCom, Inc. (DXCM) on Substack by Na’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc. (DXCM)’s share was trading at $81.53 as of May 5th. DXCM’s trailing and forward P/E were 61.30 and 40.65 respectively according to Yahoo Finance. Dexcom, Inc. stands at the […]
Why Apellis Pharmaceuticals Wilted on Wednesday
Unfortunately, it missed analyst estimates on both the top and bottom lines. A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (NASDAQ: APLS) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (SNPINDEX: ^GSPC) closed in the black with a 0.4% gain.
Why Apellis Pharmaceuticals Wilted on Wednesday
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -105.56% and 13.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: PBYI
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4%...
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: RYTM
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
Why Acadia Healthcare Company, Inc. (ACHC) is Among the Best Oversold NASDAQ Stocks to Buy Right Now
We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Acadia Healthcare Company, Inc. (NASDAQ:ACHC) stands against other oversold NASDAQ stocks to buy right now. On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on […]
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ARVN
Qualcomm reinstated, Arista upgraded: Wall Street's top analyst calls
Qualcomm reinstated, Arista upgraded: Wall Street's top analyst calls
Why Stellantis N.V. (STLA) Lagged Performance on Wednesday
We recently published an article titled These 10 Firms Led Lagged Performance on Wednesday. In this article, we are going to take a look at where Stellantis N.V. (NYSE:STLA) stands against the other stocks. Wall Street’s major indices finished in the green territory anew on Wednesday as worries about tariff policies and the Federal Reserve’s independence […]
Why Super Micro Computer Stock Is Soaring Today
Super Micro Computer (NASDAQ: SMCI) stock is rocketing higher Wednesday in response to multiple positive catalysts. At the same point in the session, the S&P 500 had risen 1.8%, and the Nasdaq Composite was up 2.9%. Supermicro's valuation is climbing today thanks to a combination of encouraging developments on the macroeconomic front.
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]
Apellis Announces Craig Wheeler to Join the Board of Directors
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief...
Apellis Announces Craig Wheeler to Join the Board of Directors
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today...